Evidence map›Paper›PMID 42190999›Full record

ArticleInternational journal of pharmaceutics2026

Electrospun nanofibers for antibiotic and probiotic co-delivery to target bacterial vaginosis.

Davis Verhoeven, Anthony J Kyser, Arielle Greiner, Warren G Lewis, Amanda L Lewis, Hermann B Frieboes

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of pharmaceutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Davis VerhoevenDepartment of Bioengineering, University of Louisville Speed School of Engineering, Louisville, KY 40202, USA.
Anthony J KyserDepartment of Bioengineering, University of Louisville Speed School of Engineering, Louisville, KY 40202, USA.
Arielle GreinerDepartment of Bioengineering, University of Louisville Speed School of Engineering, Louisville, KY 40202, USA.
Warren G LewisDepartment of Obstetrics, Gynecology and Reproductive Sciences, University of California San Diego, La Jolla, CA, USA; Glycobiology Research and Training Center, University of California San Diego, La Jolla, CA, USA.
Amanda L LewisDepartment of Obstetrics, Gynecology and Reproductive Sciences, University of California San Diego, La Jolla, CA, USA; Glycobiology Research and Training Center, University of California San Diego, La Jolla, CA, USA.
Hermann B FrieboesDepartment of Bioengineering, University of Louisville Speed School of Engineering, Louisville, KY 40202, USA; Center for Predictive Medicine, University of Louisville, Louisville, KY 40202, USA; Department of Pharmacology and Toxicology, University of Louisville School of Medicine, Louisville, KY 40202, USA; UofL Health - Brown Cancer Center, University of Louisville, KY 40202, USA. Electronic address: hbfrie01@louisville.edu.

Funding

3D-bioprinting of sustained- and phased-release antibiotic and probiotic scaffolds to treat bacterial vaginosisR01AI168475 · NIAID · UNIVERSITY OF LOUISVILLE · PI FRIEBOES, HERMANN, LEWIS, AMANDA L. · 2022 to 2025
$3.0M
Understanding the Host-Microbiome-Therapeutic Triad: Implications for Designing Alternative Intravaginal Delivery Platforms to Treat Bacterial VaginosisR01AI139671 · NIAID · UNIVERSITY OF LOUISVILLE · PI FRIEBOES, HERMANN, LEWIS, AMANDA L. · 2019 to 2023
$2.5M
NIAID NIH HHS R01 AI139671NIAID NIH HHS R01 AI168475
6 · The paper itself

Abstract

Despite initial success, antibiotic therapy for bacterial vaginosis (BV) often fails within a year to prevent recurrence. Probiotic therapy has shown promise, but inconvenient and frequent administration may affect user adherence. Recently, probiotic (lactobacilli) therapy alone was shown insufficient to dislodge fastidious anaerobic bacteria such as Gardnerella. Nanofiber devices offer a means for controlled delivery of active agents for vaginal application. This study developed a novel nanofiber vehicle for antibiotic and probiotic co-delivery with the goal of targeting anaerobes while simultaneously promoting lactobacilli. Nanofibers were designed with 3:1 v/v PEO:PLGA ratio in a meshed architecture. Fibers were loaded with 7.5 mg metronidazole and 8.33x10

Indexed as

Anti-Bacterial AgentsMetronidazoleNanofibersProbioticsVaginosis, BacterialDrug Delivery SystemsDrug LiberationFemaleHumansLactic AcidLactobacillus crispatusPolyglycolic AcidPolylactic Acid-Polyglycolic Acid CopolymerAnti-Bacterial AgentsLactic AcidMetronidazolePolyglycolic AcidPolylactic Acid-Polyglycolic Acid CopolymerBacterial vaginosisElectrospinningLactobacillus crispatusMetronidazoleNanofibers

Identifiers

PMID42190999
PMCPMC13274730

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.